Tossemide
Reading File
Finding Sources
Searching PubMed
torsemide
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
I now have all the information needed for a comprehensive answer. Let me compile it.
Torsemide
Overview
Torsemide (brand name: Demadex) is a sulfonamide-based loop diuretic - the most efficacious class of diuretics available. It is structurally similar to furosemide and bumetanide, acting on the thick ascending limb (TAL) of the loop of Henle.
Mechanism of Action
Torsemide inhibits NKCC2 (the Na+/K+/2Cl- cotransporter) on the luminal (apical) membrane of TAL cells. This transporter is a member of the solute carrier family SLC12A1.
By blocking NKCC2:
- Na+ and Cl- reabsorption in the TAL is abolished
- The lumen-positive transepithelial potential is reduced (since K+ recycling via ROMK channels is disrupted)
- This reduced potential also decreases paracellular reabsorption of Ca2+ and Mg2+, increasing their urinary excretion
The Na+/K+-ATPase on the basolateral membrane provides the driving force for the transporter. Loop diuretics bind NKCC2 from the luminal surface and are therefore delivered via tubular secretion in the proximal tubule.
Loop diuretics also induce COX-2 expression, leading to synthesis of PGE2, which further inhibits salt transport in the TAL. NSAIDs can blunt this prostaglandin-mediated component.
- Katzung's Basic and Clinical Pharmacology, 16th Ed., p. 406-408
- Brenner and Rector's The Kidney, p. 2257
Pharmacokinetics: Torsemide vs. Other Loop Diuretics
| Parameter | Torsemide | Furosemide | Bumetanide |
|---|---|---|---|
| Oral bioavailability | ~80-90% (very consistent) | Variable (10-100%) | ~80% |
| Onset (oral) | ~1 hour | 2-3 hours | ~1 hour |
| Duration of effect | 4-6 hours | 2-3 hours | 4-6 hours |
| Elimination | Primarily hepatic | Primarily renal | 50% hepatic / 50% renal |
| Active metabolites | Yes (longer t½ than parent) | Minimal | No |
Key advantage of torsemide: Its consistent oral bioavailability makes dosing far more predictable compared to furosemide, where absorption can be erratic (especially in heart failure with gut edema).
Torsemide has an active metabolite with a longer half-life than the parent compound, which may contribute to its prolonged effect.
- Katzung's Basic and Clinical Pharmacology, 16th Ed., p. 407
Dosing
| Drug | Oral Daily Dose | Equivalent Dose |
|---|---|---|
| Torsemide | 5-20 mg | 10 mg |
| Furosemide | 20-80 mg | 20 mg |
| Bumetanide | 0.5-2 mg | 0.5 mg |
| Ethacrynic acid | 50-200 mg | ~50 mg |
Torsemide is twice as potent as furosemide on a mg-for-mg basis (10 mg torsemide ≈ 20 mg furosemide).
Clinical Indications
- Edema - CHF, hepatic cirrhosis, nephrotic syndrome, chronic renal failure
- Hypertension - especially with renal insufficiency
- Acute pulmonary edema
- Hypercalcemia - combined with saline infusion to force Ca2+ excretion
- Hyperkalemia - enhances urinary K+ excretion (use with normal saline if euvolemic)
- Acute renal failure - increases urine flow and K+ excretion (does not reverse or shorten ARF)
- Anion overdose (bromide, fluoride, iodide) - these anions are reabsorbed in TAL
Adverse Effects
| Effect | Mechanism |
|---|---|
| Hypokalemic metabolic alkalosis | Increased Na+ delivery to collecting duct → enhanced K+ and H+ secretion by principal cells |
| Ototoxicity | Inhibition of NKCC1 in inner ear, disturbing endolymph ion concentrations; torsemide has no clinical ototoxicity unlike furosemide |
| Hyperuricemia / gout | Hypovolemia-associated increased uric acid reabsorption in proximal tubule |
| Hypomagnesemia | Loss of lumen-positive potential reduces Mg2+ reabsorption in TAL |
| Hypercalciuria / mild hypocalcemia | Same mechanism as Mg2+ (BUT loop diuretics can worsen hypercalcemia in occult malignancy + volume depletion) |
| Sulfonamide allergy | Skin rash, eosinophilia, interstitial nephritis (rare cross-reactivity) |
| Dehydration / hypovolemia | Loss of medullary concentrating gradient impairs downstream water reabsorption |
| Thiamine deficiency worsening | Long-term use in heart failure patients |
Note on ototoxicity: Torsemide notably has no clinical ototoxicity documented, compared to furosemide and bumetanide. This is an important clinical distinction from the other loop diuretics. - Cummings Otolaryngology
Anti-Aldosteronism Effect (Unique to Torsemide)
Torsemide (torasemide) has a documented anti-aldosteronism/anti-fibrotic effect not shared by furosemide. It inhibits aldosterone-mediated effects, which may partly explain its potential benefit in reducing cardiac fibrosis and hospitalizations in heart failure patients.
Torsemide vs. Furosemide in Heart Failure
Recent meta-analyses (2024-2025) continue to investigate this comparison:
- Study results are inconsistent, but there may be a benefit of torsemide over furosemide in decreasing hospitalizations and possibly reducing acute kidney injury episodes in heart failure
- A mortality benefit has not been demonstrated in any study
- The more consistent bioavailability of torsemide is a practical clinical advantage
Two recent systematic reviews address this:
- Teixeira et al. 2024 - Arq Bras Cardiol (PMID: 39046046) - torsemide vs. furosemide in HF
- Gudushauri et al. 2025 - Acta Cardiol (PMID: 39910952) - mortality and rehospitalization outcomes
Contraindications and Drug Interactions
- Sulfonamide hypersensitivity - rare cross-reactivity with furosemide, bumetanide, torsemide
- NSAIDs - reduce diuretic efficacy by inhibiting prostaglandin synthesis (particularly significant in nephrotic syndrome or hepatic cirrhosis)
- Probenecid / other weak acids - compete for proximal tubule secretion, reducing tubular delivery of the drug
- Aminoglycosides - increased risk of ototoxicity (additive)
- Caution in hepatic cirrhosis, borderline renal failure, heart failure (avoid overzealous diuresis)
Summary Table: Key Features of Torsemide
| Property | Detail |
|---|---|
| Class | Sulfonamide loop diuretic |
| Target | NKCC2 (luminal side, TAL) |
| Bioavailability | ~80-90%, consistent |
| Oral onset | ~1 hour |
| Duration | 4-6 hours |
| Metabolism | Hepatic (unlike furosemide) |
| Potency | 10 mg = 20 mg furosemide |
| Ototoxicity | None documented clinically |
| Special feature | Anti-aldosterone/anti-fibrotic effect |
Sources: Katzung's Basic and Clinical Pharmacology 16th Ed., pp. 406-409 | Brenner & Rector's The Kidney | Cummings Otolaryngology
This is a shared conversation. Sign in to Orris to start your own chat.